TNFSF10 and diabetes mellitus: Moreover, the adjustment for diabetes and statin treatments, two established modulators of atheromatosis progression [30], confirmed that low levels of circulating TRAIL associated to the appearance of at least two new atheromatous plaques after 24-months of follow-up.